drugset
Drugs / SARS-CoV-2 Specific T Cells
last change Dec 2022 re-read 3 minutes ago

SARS-CoV-2 Specific T Cells

Cell therapy

Developed for
COVID-19
Investigated by
Changi General Hospital · Duke-NUS Graduate Medical School · KK Women's and Children's Hospital · National University Hospital, Singapore · Sengkang General Hospital · Singapore General Hospital

Trials 1

today NCT04457726 · Ph 1/2
202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT04457726 Jul 2020 → Mar 2021 COVID-19 KK Women's and Children's Hospital Unknown No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as SARS-CoV-2 Specific T Cells ClinicalTrials.gov intervention name — accepted as the source's own label NCT04457726 ↗
Modality Cell therapy “adoptive T-cell therapy” NCT04457726 ↗
Route Intravenous “single infusion of SARS-CoV-2 specific T cells intravenously.” NCT04457726 ↗